Home LiteratureArticle Details

PMID: 19923549 Published · ppublish English Editorial Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Comment

APOE {epsilon}4 and bapineuzumab: Infusing pharmacogenomics into Alzheimer disease therapeutics.

Neurology ·Vol. 73 ·No. 24 ·2009-12-15 ·Pages 2052-3

Kaufer D, Gandy S

Abstract

暂无摘要

MeSH Terms

Alzheimer Disease/drug therapy,genetics,psychology Amyloid beta-Peptides/immunology Antibodies, Monoclonal/administration & dosage,adverse effects,immunology,therapeutic use Antibodies, Monoclonal, Humanized Apolipoprotein E4/genetics Cognition/drug effects Heterozygote Humans Injections, Intravenous Treatment Outcome

Chemicals

Amyloid beta-Peptides Antibodies, Monoclonal Antibodies, Monoclonal, Humanized Apolipoprotein E4 bapineuzumab

Authors & Affiliations

2 authors, click to expand affiliations / ORCID

Kaufer Dan

Gandy Sam

Article Info

Journal

Neurology

Abbr.

Neurology

ISSN

1526-632X

DOI

10.1212/WNL.0b013e3181c6784a

Published

2009-12-15

Epub

2009-00-18

Pages

2052-3

Language

English

Region

United States

NLM ID

0401060

Subset

Grants

NIA NIH HHS · R01 AG022462 · United States

NIMH NIH HHS · R01 MH086633 · United States

NIA NIH HHS · P50 AG005138 · United States

NIA NIH HHS · P01 AG10491 · United States

NIA NIH HHS · R21 AG033387 · United States

NIA NIH HHS · R21AG033387 · United States

NCIPC CDC HHS · R49CE001495 · United States

NIA NIH HHS · P01 AG010491 · United States

NIBIB NIH HHS · K01 EB009724 · United States

Corrections

CommentOn

PMID: 19923550

External Links

PubMed source DOI: 10.1212/WNL.0b013e3181c6784a View journal details

Analysis Services

APOE {epsilon}4 and bapineuzumab: Infusing pharmacogenomics into Alzheimer disease therapeutics.

Contact

WeChat Official Account